相关实验视频
Updated: Jul 13, 2026

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.6K
作为治疗癌症转移目标的MDA-9/Syntenin:当前的分子和临床前理解
Swadesh K Das1,2,3, Paul B Fisher1,2,3
1VCU Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Expert opinion on therapeutic targets
|March 8, 2025
概括
转移是癌症死亡的主要原因,需要新的治疗方法. 向黑色素瘤分化相关基因-9 (MDA-9/Syntenin) 显示出开发强效抗转移药物的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症转移研究 癌症转移研究
背景情况:
- 转移是癌症发病率和死亡率的主要驱动因素,目前的治疗方法往往不足.
- 初级瘤和转移之间的基因组异质性使得向治疗的开发变得复杂.
- 现有的免疫疗法面临挑战,包括毒性,免疫抵抗和瘤微环境 (TME) 因素.
研究的目的:
- 确定关键的分子标,以开发有效的抗转移药物.
- 研究黑色素瘤分化相关基因-9 (MDA-9/Syntenin) 在癌症转移中的作用.
- 探索针对MDA-9/Syntenin用于新型抗癌疗法的潜力.
主要方法:
- 主要和转移性瘤克隆的基因组分析.
- 研究涉及转移级联的信号通路.
- 评估MDA-9/Syntenin表达和功能在癌症进展中的作用.
主要成果:
- 黑色素瘤分化关联基因-9 (MDA-9/Syntenin) 是高度表达的,对癌症进展至关重要.
- MDA-9/Syntenin与其他转移相关的分子和途径相互作用.
- 针对MDA-9/Syntenin的第一类抑制剂正在出现,并显示出治疗潜力.
结论:
- 向MDA-9/Syntenin代表了开发新型抗转移疗法的有希望的战略.
- 了解MDA-9/Syntenin的分子机制是克服转移性癌症治疗挑战的关键.
- 进一步开发MDA-9/Syntenin抑制剂可能会改善晚期癌症患者的治疗结果.
相关概念视频
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...

